• Investors
  • Contact
  • Privacy Policy
  • Healthcare Professionals

    A novel approach to glaucoma treatment

    The treatment of glaucoma is undergoing a renaissance. From the advent of minimally invasive glaucoma surgery (MIGS), through to new pharmacological agents which overcome the challenges associated with patient compliance, there are now a myriad of glaucoma treatment options. What does this mean for glaucoma patients?

    No longer must surgeons take a wait-and-see approach, monitoring patients until structural and functional damage to the optic nerve is considered severe enough to warrant trabeculectomy or tube shunt surgery. Instead, surgeons can now intervene earlier via a number of minimally invasive treatment options to effectively reduce IOP, with the potential to reduce long-term reliance on anti-glaucoma medications and, in some cases, avoid the need for more invasive surgical options.

    Nova Eye Medical is at the forefront of efforts to support this shift towards a more proactive, interventional approach to glaucoma treatment. Our proprietary technologies include the iTrack™ family of canaloplasty devices. Not only does canaloplasty comprehensively treat all aspects of the conventional outflow pathway, but it does so without the need to place a stent and without the need to remove or tear tissue. For cases of advanced and complex glaucoma, our Molteno3® glaucoma drainage device technology provides a trusted treatment innovation.

    A hallmark of the glaucoma treatment renaissance is that, not only does it allow us to intervene earlier in the treatment of our glaucoma patients, but it enables us to adopt a truly nuanced treatment approach. Traditional surgical options, while effective, have typically been a one-size-fits-all’ approach – and we know that the pathophysiology of glaucoma differs markedly from patient to patient. It makes sense that our treatment options also differ, patient to patient. The recent explosion in glaucoma treatments allows us to optimize patient outcomes – avoiding both vision loss and possibly a lifetime of medication use and, in some cases, eliminating the need for more invasive surgical options.

    The iTrack™ Advance has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma. — — — — — — — – INDICATIONS (USA): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.*  The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.  The ab interno surgical technique is not a cleared indication of the iTrack Advance in the USA * The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.  CONTRAINDICATIONS (USA): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.  PRECAUTIONS (USA): The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.  — — — — — — — – INDICATIONS (International): The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open angle glaucoma.  CONTRAINDICATIONS (International): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.  ADVERSE EVENTS (International): Possible adverse events with the use of the iTrack™ Advance include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.  PRECAUTIONS (International):: The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.  For full safety information, visit: https://​itrack​-advance​.com © 2025. Nova Eye, Inc. E&OE. Patents pending and/​or granted. 
    iTrack™ Advance, iTrack™, ViscoInjector™ and iLumin™ are trademarks of Nova Eye, Inc.
    This website uses cookies to ensure you get the best experience on our website.
    The cookies do not store any personalised information. Learn More